Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Bintrafusp alfa + CV301 + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Bintrafusp alfa | MSB0011359C|M7824 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 TGFBR2 Antibody 3 | Bintrafusp alfa is a human PD-L1 (CD274) antibody fused with transforming growth factor-beta (TGF-beta, TGFBR2) receptor II extracellular domain, which blocks two immuno-inhibitory pathways simultaneously, therefore enhances anti-tumor immunity (PMID: 29298798, PMID: 32461347). | |
CV301 | CV-301|PANVAC|CV301-V/F|BN-CV301 | CV301 is a poxvirus-based vaccine that encodes tumor antigens CEA and MUC-1, and 3 costimulatory molecules including B7.1, ICAM-1, and LFA-3, which may stimulate antitumor immune response (PMID: 31110074). | ||
PROSTVAC-F-TRICOM | PROSTVAC-F-TRICOM is a cancer vaccine consisting of a recombinant fowlpox virus encoding PSA and TRICOM (a combination of B7.1, ICAM-1, and LFA-3), which induces antitumor immune response against PSA-positive tumors (PMID: 16390546). | |||
PROSTVAC-V-TRICOM | PROSTVAC-V-TRICOM is a cancer vaccine consisting of a recombinant vaccinia virus encoding PSA and TRICOM (a combination of B7.1, ICAM-1, and LFA-3) which induces antitumor immune response against PSA-positive tumors (PMID: 16390546). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03315871 | Phase II | Bintrafusp alfa + CV301 + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM | Combination Immunotherapy in Biochemically Recurrent Prostate Cancer | Active, not recruiting | USA | 0 |